ISRG Quote, Financials, Valuation and Earnings

Perspective Therapeutics has a net margin of 27.73% compared to Intuitive Surgical's net margin of --. Intuitive Surgical's return on equity of 15.9% beat Perspective Therapeutics's return on equity of --.

Intuitive Surgical has a consensus price target of $556.42, signalling upside risk potential of 4.03%. On the other hand Perspective Therapeutics has an analysts' consensus of $16.15 which suggests that it could grow by 406.27%. Given that Perspective Therapeutics has higher upside potential than Intuitive Surgical, analysts believe Perspective Therapeutics is more attractive than Intuitive Surgical.

Intuitive Surgical has a beta of 1.383, which suggesting that the stock is 38.272% more volatile than S&P 500. In comparison Perspective Therapeutics has a beta of 1.129, suggesting its more volatile than the S&P 500 by 12.894%.

Intuitive Surgical has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Perspective Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Intuitive Surgical pays -- of its earnings as a dividend. Perspective Therapeutics pays out -- of its earnings as a dividend.

Intuitive Surgical quarterly revenues are $2B, which are larger than Perspective Therapeutics quarterly revenues of --. Intuitive Surgical's net income of $565.1M is higher than Perspective Therapeutics's net income of -$15.1M. Notably, Intuitive Surgical's price-to-earnings ratio is 85.99x while Perspective Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Intuitive Surgical is 24.52x versus 17.23x for Perspective Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Glaukos has a net margin of 27.73% compared to Intuitive Surgical's net margin of -22.15%. Intuitive Surgical's return on equity of 15.9% beat Glaukos's return on equity of -27.46%.

Intuitive Surgical has a consensus price target of $556.42, signalling upside risk potential of 4.03%. On the other hand Glaukos has an analysts' consensus of -- which suggests that it could fall by -2.59%. Given that Intuitive Surgical has higher upside potential than Glaukos, analysts believe Intuitive Surgical is more attractive than Glaukos.

Intuitive Surgical has a beta of 1.383, which suggesting that the stock is 38.272% more volatile than S&P 500. In comparison Glaukos has a beta of 1.034, suggesting its more volatile than the S&P 500 by 3.395%.

Intuitive Surgical has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Glaukos offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Intuitive Surgical pays -- of its earnings as a dividend. Glaukos pays out -- of its earnings as a dividend.

Intuitive Surgical quarterly revenues are $2B, which are larger than Glaukos quarterly revenues of $96.7M. Intuitive Surgical's net income of $565.1M is higher than Glaukos's net income of -$21.4M. Notably, Intuitive Surgical's price-to-earnings ratio is 85.99x while Glaukos's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Intuitive Surgical is 24.52x versus 21.42x for Glaukos. Usually stocks with elevated PS ratios are considered overvalued.

PROCEPT BioRobotics has a net margin of 27.73% compared to Intuitive Surgical's net margin of -35.93%. Intuitive Surgical's return on equity of 15.9% beat PROCEPT BioRobotics's return on equity of -37.42%.

Intuitive Surgical has a consensus price target of $556.42, signalling upside risk potential of 4.03%. On the other hand PROCEPT BioRobotics has an analysts' consensus of $102.75 which suggests that it could grow by 25.29%. Given that PROCEPT BioRobotics has higher upside potential than Intuitive Surgical, analysts believe PROCEPT BioRobotics is more attractive than Intuitive Surgical.

Intuitive Surgical has a beta of 1.383, which suggesting that the stock is 38.272% more volatile than S&P 500. In comparison PROCEPT BioRobotics has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Intuitive Surgical has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. PROCEPT BioRobotics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Intuitive Surgical pays -- of its earnings as a dividend. PROCEPT BioRobotics pays out -- of its earnings as a dividend.

Intuitive Surgical quarterly revenues are $2B, which are larger than PROCEPT BioRobotics quarterly revenues of $58.4M. Intuitive Surgical's net income of $565.1M is higher than PROCEPT BioRobotics's net income of -$21M. Notably, Intuitive Surgical's price-to-earnings ratio is 85.99x while PROCEPT BioRobotics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Intuitive Surgical is 24.52x versus 21.06x for PROCEPT BioRobotics. Usually stocks with elevated PS ratios are considered overvalued.

Stryker has a net margin of 27.73% compared to Intuitive Surgical's net margin of 15.18%. Intuitive Surgical's return on equity of 15.9% beat Stryker's return on equity of 18.78%.

Intuitive Surgical has a consensus price target of $556.42, signalling upside risk potential of 4.03%. On the other hand Stryker has an analysts' consensus of $406.60 which suggests that it could grow by 10.76%. Given that Stryker has higher upside potential than Intuitive Surgical, analysts believe Stryker is more attractive than Intuitive Surgical.

Intuitive Surgical has a beta of 1.383, which suggesting that the stock is 38.272% more volatile than S&P 500. In comparison Stryker has a beta of 0.938, suggesting its less volatile than the S&P 500 by 6.217%.

Intuitive Surgical has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Stryker offers a yield of 0.87% to investors and pays a quarterly dividend of $0.80 per share. Intuitive Surgical pays -- of its earnings as a dividend. Stryker pays out 35.99% of its earnings as a dividend. Stryker's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Intuitive Surgical quarterly revenues are $2B, which are smaller than Stryker quarterly revenues of $5.5B. Intuitive Surgical's net income of $565.1M is lower than Stryker's net income of $834M. Notably, Intuitive Surgical's price-to-earnings ratio is 85.99x while Stryker's PE ratio is 39.35x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Intuitive Surgical is 24.52x versus 6.43x for Stryker. Usually stocks with elevated PS ratios are considered overvalued.